FMC Corporation Earnings Recaps
The stock gained 7.0% on the news that first quarter results surpassed expectations, driven by better-than-anticipated sales volume, foreign exchange benefits, and cost controls that fueled EBITDA upside.
Key takeaways
- First quarter sales of $762 million came in $12 million above the midpoint of guidance, despite a 4% year-over-year decline.
- Volume increased 2% with a 5% positive foreign exchange impact; FMC-branded sales grew 6% on a like-for-like basis, led by EMEA and North America herbicides and Cyazypyr.
- Price declined 6%, largely due to diamide partner volumes and Rynaxypyr price repositioning as part of the post-patent strategy.
- Adjusted EBITDA reached $72 million, exceeding guidance by $17 million, benefiting from favorable FX, volume, and cost improvements.
- Adjusted loss per share was $0.23, $0.15 better than the midpoint of guidance, reflecting improved operational efficiency and FX gains.
FMC shares closed up 1.2% following first quarter results that modestly surpassed internal guidance midpoints. Performance was mixed, as FX and volume supported modest outperformance, but sales and margins reflected ongoing market competition and pressure from generics.
Key takeaways
- First quarter sales totaled $762 million, $12 million above FMC’s guidance midpoint; sales declined 4% year-over-year, but rose 1% excluding India.
- EBITDA reached $72 million, exceeding the high end of guidance by $17 million, with FX, volume, and cost controls all contributing favorably.
- Sales of new active ingredients doubled year-over-year, while core portfolio performance lagged due to competitive pricing and post-patent headwinds, especially in LatAm and Asia.
- Price declined 6% overall, nearly half attributed to lower pricing to diamide partners and the rest driven by branded Rynaxypyr repositioning and pressure on legacy products.
- Strategic initiatives advanced, including progress on $1 billion in targeted debt reduction and the late-stage sale process of the India commercial business; Board continues to evaluate broader alternatives.
FMC Corporation reported a challenging third quarter with net sales declining 49% year-over-year, largely due to inventory adjustments in India and price pressures in Latin America. Adjusted EBITDA improved 17%, reflecting disciplined cost management despite external pressures.
Key takeaways
- Third quarter GAAP net sales reached $542 million, significantly impacted by India's inventory actions and Brazil's credit constraints.
- Excluding India, revenue fell 4% year-over-year, driven by a 6% price decline and an 8% sales lag in Latin America.
- Adjusted EBITDA was $236 million, up 17% year-over-year, benefiting from strong cost control and increased demand for new active ingredients.
- Adjusted EPS improved 30%, reaching $0.89, supported by the enhanced EBITDA performance.
- Anticipated fourth quarter sales (excluding India) are projected between $1.12 billion and $1.22 billion, with continued pricing pressures expected.
FMC Corporation delivered solid second quarter results with adjusted EBITDA of $207 million and adjusted EPS of $0.69, slightly exceeding guidance. The company is transitioning its operations in India while focusing on growth opportunities in key markets.
Key takeaways
- Sales increased 1% year-over-year, supported by a 6% volume growth amidst completed channel destocking.
- Adjusted EBITDA rose 2% compared to the prior year due to lower costs and improved fixed cost absorption.
- Upcoming product launches, including fluindapyr and pheromones, are set to enhance growth in the second half of 2025.
- The company plans to divest its commercial operations in India to streamline operations and improve working capital efficiency.